Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine... see more

NDAQ:PMN - Post Discussion

ProMIS Neurosciences Inc > PMN has quality science
View:
Post by Gbathat on Dec 09, 2020 10:10am

PMN has quality science

For those who question the level of science from PMN, and who are not convinced by the featured presentations by Dr. Cashman at the leading symposia in this field, I'd like to point out the that PMN310 paper was published in one of the most rigorously peer reviewed journals in the world.

https://www.nature.com/srep/about

Scientific Reports is the 7th most-cited journal in the world, with more than 350,000 citations in 2019*, and receives widespread attention in policy documents and the media.

Here is a link to the article

https://pubmed.ncbi.nlm.nih.gov/31285517/
Comment by Actuarial on Dec 09, 2020 10:27am
No one question the science, we just question if the management team ever be able to bring PMN through clinical ...... with no cash, no plan ......
Comment by farmerjane on Dec 09, 2020 1:05pm
Pharma finds quality science, but after a few years of pharma discussions what's really going on? They have a plan but is it in all shareholders interest?
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities